JP2013529059A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529059A5
JP2013529059A5 JP2012556526A JP2012556526A JP2013529059A5 JP 2013529059 A5 JP2013529059 A5 JP 2013529059A5 JP 2012556526 A JP2012556526 A JP 2012556526A JP 2012556526 A JP2012556526 A JP 2012556526A JP 2013529059 A5 JP2013529059 A5 JP 2013529059A5
Authority
JP
Japan
Prior art keywords
region
seq
sequence
antibody
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012556526A
Other languages
English (en)
Japanese (ja)
Other versions
JP6055312B2 (ja
JP2013529059A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/053646 external-priority patent/WO2011110642A2/en
Publication of JP2013529059A publication Critical patent/JP2013529059A/ja
Publication of JP2013529059A5 publication Critical patent/JP2013529059A5/ja
Application granted granted Critical
Publication of JP6055312B2 publication Critical patent/JP6055312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2012556526A 2010-03-10 2011-03-10 Ｃ−ｍｅｔに対するモノクローナル抗体 Active JP6055312B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31262210P 2010-03-10 2010-03-10
DKPA201000191 2010-03-10
DKPA201000191 2010-03-10
US61/312,622 2010-03-10
DKPA201000862 2010-09-24
DKPA201000862 2010-09-24
PCT/EP2011/053646 WO2011110642A2 (en) 2010-03-10 2011-03-10 Monoclonal antibodies against c-met

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016121630A Division JP6348541B2 (ja) 2010-03-10 2016-06-20 Ｃ−ｍｅｔに対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2013529059A JP2013529059A (ja) 2013-07-18
JP2013529059A5 true JP2013529059A5 (2) 2014-04-24
JP6055312B2 JP6055312B2 (ja) 2017-01-11

Family

ID=44342987

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012556526A Active JP6055312B2 (ja) 2010-03-10 2011-03-10 Ｃ−ｍｅｔに対するモノクローナル抗体
JP2016121630A Active JP6348541B2 (ja) 2010-03-10 2016-06-20 Ｃ−ｍｅｔに対するモノクローナル抗体
JP2018104445A Active JP6697027B2 (ja) 2010-03-10 2018-05-31 Ｃ−ｍｅｔに対するモノクローナル抗体
JP2020076411A Active JP7034204B2 (ja) 2010-03-10 2020-04-23 Ｃ－ｍｅｔに対するモノクローナル抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016121630A Active JP6348541B2 (ja) 2010-03-10 2016-06-20 Ｃ−ｍｅｔに対するモノクローナル抗体
JP2018104445A Active JP6697027B2 (ja) 2010-03-10 2018-05-31 Ｃ−ｍｅｔに対するモノクローナル抗体
JP2020076411A Active JP7034204B2 (ja) 2010-03-10 2020-04-23 Ｃ－ｍｅｔに対するモノクローナル抗体

Country Status (26)

Country Link
US (6) US9068011B2 (2)
EP (4) EP2545077B1 (2)
JP (4) JP6055312B2 (2)
KR (2) KR102059663B1 (2)
CN (2) CN107739407B (2)
AU (4) AU2011226103C1 (2)
BR (1) BR112012022672B1 (2)
CA (3) CA2791863C (2)
DK (1) DK3904391T3 (2)
EA (1) EA201201273A1 (2)
ES (1) ES2993335T3 (2)
FI (1) FI3904391T3 (2)
HR (1) HRP20241246T1 (2)
HU (1) HUE068433T2 (2)
IL (1) IL221408B (2)
LT (1) LT3904391T (2)
MX (1) MX340295B (2)
NZ (1) NZ602294A (2)
PH (1) PH12012501793B1 (2)
PL (1) PL3904391T3 (2)
PT (1) PT3904391T (2)
RS (1) RS66008B1 (2)
SG (2) SG10201501767VA (2)
SI (1) SI3904391T1 (2)
SM (1) SMT202400403T1 (2)
WO (1) WO2011110642A2 (2)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
JP6219287B2 (ja) * 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
US9346884B2 (en) * 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2785741A1 (en) * 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9708601B2 (en) * 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
CN105050618B (zh) * 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
JP2014157056A (ja) * 2013-02-15 2014-08-28 Fujirebio Inc ｃ−ＭＥＴ遺伝子増幅細胞の検出方法
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
EP2787008B1 (en) * 2013-04-02 2019-09-04 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-C-met antibody
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
EA039356B1 (ru) * 2013-10-18 2022-01-18 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
SI3071237T1 (sl) 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
KR101615619B1 (ko) * 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN108350078A (zh) * 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
MA45412A (fr) 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
MX420249B (es) 2016-09-29 2025-02-10 Mitsubishi Tanabe Pharma Corp Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos.
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP4218817A3 (en) 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
CN106831995A (zh) * 2017-03-31 2017-06-13 北京百特美博生物科技有限公司 新型双特异性抗体及其用途
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
JP7325339B2 (ja) * 2017-05-30 2023-08-14 チョン クン ダン ファーマシューティカル コーポレーション 新規な抗ｃ－Ｍｅｔ抗体およびその用途
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN119101158A (zh) 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
SG11202009258RA (en) 2018-03-23 2020-10-29 Univ Texas Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
JP7169705B2 (ja) * 2018-07-10 2022-11-11 ジーンメディスン・カンパニー・リミテッド 抗腫瘍組成物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
US20220267467A1 (en) * 2019-07-19 2022-08-25 WuXi Biologics Ireland Limited Polypeptide complex for conjugation and use thereof
WO2021022304A2 (en) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CN111620944B (zh) * 2020-06-01 2023-03-21 长春师范大学 一种全人源化抗乙肝病毒单克隆抗体、制备方法及其应用
CN112521507B (zh) * 2020-08-10 2021-06-08 北京鼎成肽源生物技术有限公司 抗人c-Met人鼠嵌合单克隆抗体及其应用
CN116194141A (zh) 2020-08-25 2023-05-30 詹森生物科技公司 具有egfr突变的非小细胞肺癌的治疗
WO2022152289A1 (en) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. An engineered antibody and antibody-drug conjugates comprisign same
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
AU2022297542A1 (en) * 2021-06-25 2024-01-04 Academia Sinica Combined cancer therapy with an epithelial cell adhesion molecule (epcam) inhibitor and a hepatocyte growth factor receptor (hgfr) inhibitor
CN113621058B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 黄热病毒抗体及其应用
CN118354789A (zh) * 2021-09-03 2024-07-16 Go医疗股份有限公司 抗糖-cMET抗体及其用途
CN116178530A (zh) * 2021-09-26 2023-05-30 上海君实生物医药科技股份有限公司 抗体在治疗SARS-CoV-2感染的用途
CN116725960A (zh) * 2022-03-11 2023-09-12 上海君实生物医药科技股份有限公司 新型冠状病毒抗体药物组合物及其用途
WO2023186092A1 (zh) 2022-04-02 2023-10-05 普米斯生物技术(珠海)有限公司 针对c-Met的单克隆抗体以及双特异性抗体
IL318499A (en) 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
CN121293352A (zh) * 2023-01-19 2026-01-09 广州百济神州生物制药有限公司 抗cmet抗体及使用方法
KR20260005269A (ko) 2023-04-24 2026-01-09 치아타이 티안큉 파마수티컬 그룹 주식회사 c-Met를 표적으로 하는 다중 특이성 항체
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025180462A1 (zh) * 2024-03-01 2025-09-04 苏州康宁杰瑞生物科技有限公司 双功能融合蛋白

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0507868A4 (en) 1989-12-27 1992-11-04 Us Commerce Diagnostic probe for detecting human stomach cancer
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0571387B1 (en) 1990-09-14 2003-12-17 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce A non-mitogenic competitive hgf antagonist
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994000764A1 (en) 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
ATE160585T1 (de) 1992-09-18 1997-12-15 Us Gov Health & Human Serv Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
US5361922A (en) 1993-04-02 1994-11-08 Beckman Instruments, Inc. Centrifuge tubes with snap plugs
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2001277854B2 (en) 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1516185A4 (en) 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
BRPI0407446A (pt) 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
PL1691837T3 (pl) 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
EP2314620B1 (en) 2004-05-27 2013-06-05 Crucell Holland B.V. Method of identifying binding molecules capable of neutralizing rabies virus
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
EP1810979B1 (en) * 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
NZ561211A (en) 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
EP1863519B1 (en) 2005-03-31 2013-09-25 The General Hospital Corporation Modulating hgf/hgfr activity for treating lymphodema
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
US8101727B2 (en) * 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2457928B1 (en) * 2007-03-13 2017-05-10 Universität Zürich Monoclonal human tumor-specific antibody
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US20080300108A1 (en) 2007-05-31 2008-12-04 Eybergen William N Torque transfer device and system
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009083009A2 (en) * 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
KR20100135780A (ko) * 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.

Similar Documents

Publication Publication Date Title
JP2013529059A5 (2)
JP7118117B2 (ja) 抗体－薬物コンジュゲートの選択的製造方法
RU2568051C2 (ru) АНТИТЕЛА К ErbB3
KR102408356B1 (ko) 항―axl 항체
CN102421802B (zh) 人源化的axl抗体
JP2023509196A5 (2)
JP2020501531A5 (2)
JP2018503380A5 (2)
CN107735093A (zh) Cd123抗体和其结合物
JP2018510617A5 (2)
JP2020502233A5 (2)
AU2019233511B2 (en) Anti C-MET antibodies
CN114502595A (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
EP2603527A1 (en) Humanized egfr antibodies
KR20230132544A (ko) 신규한 항-그렘린1 항체
CA3092169A1 (en) Pd1 binding agents
WO2021173844A1 (en) C19 c38 bispecific antibodies
JP2023516195A (ja) Ｃ１９ ｃ３８二特異性抗体
US20200339702A1 (en) De-immunised anti-erbb3 antibodies
JP2008526256A5 (2)
CN118139639A (zh) 治疗与免疫抑制b细胞相关联的癌症的方法
JP2024517760A (ja) 抗５ｔ４抗体及びその使用
CA3091307A1 (en) Csf1r binding agents
WO2021058735A1 (en) Cancer treatment with anti-met antibody compositions
KR20260018083A (ko) 항-fgfr2/pd-1 이중특이항체